The most prevalent off‐target alteration after 6 months of first‐line alectinib treatment was the NF2 mutation, a tumor suppressor in the PI3K/mTOR/Akt pathway that encodes for the merlin protein (Fig. 4A). This evidence concerns the gene NF2 and neoplasm.